A detailed history of Geode Capital Management, LLC transactions in Madrigal Pharmaceuticals, Inc. stock. As of the latest transaction made, Geode Capital Management, LLC holds 405,655 shares of MDGL stock, worth $129 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares
405,655
Previous 399,854 1.45%
Holding current value
$129 Million
Previous $112 Million 23.15%
% of portfolio
0.01%
Previous 0.01%

Shares

30 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024

BUY
$212.22 - $292.96 $1.23 Million - $1.7 Million
5,801 Added 1.45%
405,655 $86.1 Million
Q2 2024

Aug 09, 2024

BUY
$193.33 - $291.99 $10.2 Million - $15.5 Million
52,997 Added 15.28%
399,854 $112 Million
Q1 2024

May 13, 2024

BUY
$171.37 - $283.23 $1.82 Million - $3 Million
10,602 Added 3.15%
346,857 $92.6 Million
Q4 2023

Feb 13, 2024

BUY
$120.4 - $237.13 $4.79 Million - $9.44 Million
39,817 Added 13.43%
336,255 $77.8 Million
Q3 2023

Nov 13, 2023

BUY
$146.04 - $225.78 $3.67 Million - $5.67 Million
25,119 Added 9.26%
296,438 $43.3 Million
Q2 2023

Aug 11, 2023

BUY
$203.88 - $312.0 $4.74 Million - $7.26 Million
23,262 Added 9.38%
271,319 $62.7 Million
Q1 2023

May 15, 2023

BUY
$231.06 - $307.08 $2.65 Million - $3.52 Million
11,472 Added 4.85%
248,057 $60.1 Million
Q4 2022

Feb 13, 2023

BUY
$58.39 - $296.54 $396,993 - $2.02 Million
6,799 Added 2.96%
236,585 $68.7 Million
Q3 2022

Nov 14, 2022

BUY
$60.57 - $79.51 $301,880 - $396,277
4,984 Added 2.22%
229,786 $14.9 Million
Q2 2022

Aug 12, 2022

BUY
$58.04 - $100.2 $395,484 - $682,762
6,814 Added 3.13%
224,802 $16.1 Million
Q1 2022

May 13, 2022

SELL
$55.89 - $101.89 $113,456 - $206,836
-2,030 Reduced 0.92%
217,988 $21.4 Million
Q4 2021

Feb 11, 2022

BUY
$72.34 - $95.09 $1.28 Million - $1.68 Million
17,643 Added 8.72%
220,018 $18.6 Million
Q3 2021

Nov 12, 2021

BUY
$78.35 - $105.02 $334,632 - $448,540
4,271 Added 2.16%
202,375 $16.1 Million
Q2 2021

Aug 13, 2021

BUY
$97.2 - $137.59 $4.21 Million - $5.96 Million
43,308 Added 27.98%
198,104 $19.3 Million
Q1 2021

May 12, 2021

BUY
$108.54 - $125.2 $1.39 Million - $1.6 Million
12,790 Added 9.01%
154,796 $18.1 Million
Q4 2020

Feb 12, 2021

BUY
$110.06 - $133.7 $438,038 - $532,126
3,980 Added 2.88%
142,006 $15.8 Million
Q3 2020

Nov 13, 2020

SELL
$99.78 - $124.21 $76,231 - $94,896
-764 Reduced 0.55%
138,026 $16.4 Million
Q2 2020

Aug 13, 2020

SELL
$60.13 - $125.71 $7,816 - $16,342
-130 Reduced 0.09%
138,790 $15.7 Million
Q1 2020

May 14, 2020

BUY
$66.76 - $93.49 $1 Million - $1.4 Million
14,987 Added 12.09%
138,920 $9.27 Million
Q4 2019

Feb 13, 2020

BUY
$84.28 - $118.5 $1.01 Million - $1.43 Million
12,032 Added 10.75%
123,933 $11.3 Million
Q3 2019

Nov 12, 2019

BUY
$84.4 - $106.53 $205,345 - $259,187
2,433 Added 2.22%
111,901 $9.65 Million
Q2 2019

Aug 14, 2019

BUY
$91.13 - $142.5 $901,731 - $1.41 Million
9,895 Added 9.94%
109,468 $11.5 Million
Q1 2019

May 14, 2019

BUY
$103.48 - $143.84 $937,218 - $1.3 Million
9,057 Added 10.01%
99,573 $12.5 Million
Q4 2018

Feb 13, 2019

BUY
$94.77 - $215.54 $429,876 - $977,689
4,536 Added 5.28%
90,516 $10.2 Million
Q3 2018

Nov 13, 2018

BUY
$207.3 - $300.31 $1.24 Million - $1.79 Million
5,964 Added 7.45%
85,980 $18.4 Million
Q2 2018

Aug 14, 2018

BUY
$101.55 - $313.9 $2.9 Million - $8.95 Million
28,514 Added 55.36%
80,016 $22.4 Million
Q1 2018

May 15, 2018

SELL
$93.35 - $149.04 $261,099 - $416,864
-2,797 Reduced 5.15%
51,502 $6.01 Million
Q4 2017

Feb 13, 2018

BUY
$39.35 - $97.37 $720,852 - $1.78 Million
18,319 Added 50.91%
54,299 $4.98 Million
Q3 2017

Nov 14, 2017

BUY
$15.48 - $46.19 $57,895 - $172,750
3,740 Added 11.6%
35,980 $1.62 Million
Q2 2017

Aug 14, 2017

BUY
N/A
32,240
32,240 $524,000

Others Institutions Holding MDGL

About MADRIGAL PHARMACEUTICALS, INC.


  • Ticker MDGL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 17,103,400
  • Market Cap $5.42B
  • Description
  • Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product candidate is resmetirom, a liver-directed selective thyroid hormone receptor-ß agonist, which is in Phase III c...
More about MDGL
Track This Portfolio

Track Geode Capital Management, LLC Portfolio

Follow Geode Capital Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Geode Capital Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Geode Capital Management, LLC with notifications on news.